Group 1 - The core point of the news is that Link Health Biotechnology Group has signed a strategic cooperation agreement with Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1] - Bogu Tai is a new generation osteoporosis treatment drug that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The cooperation area has over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai to enter these unmet market needs [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2] - The competitive pricing strategy is expected to yield higher profit margins for Bogu Tai, with revenue realization anticipated by the end of 2026 [1]